Here's a story about what happens when a tiny biotech company gets some good news. Can-Fite BioPharma Ltd. (CANF) shares more than doubled on Wednesday after the company said its drug, Namodenoson, actually worked in a mid-stage study for a really tough type of cancer.

The drug successfully met the main goal in a Phase 2a trial for patients with pretreated pancreatic cancer. For those keeping score at home, pancreatic cancer is notoriously difficult to treat, so any positive signal is a big deal. The results showed Namodenoson led to a significant improvement in overall survival rates. Perhaps just as importantly for a drug that needs to be used long-term, the company said the treatment was "well-tolerated, with a favorable safety profile." In biotech-speak, that means it didn't make patients too sick, which is a major hurdle for many cancer therapies.

The study also looked at secondary goals like overall survival and how long patients lived without their cancer getting worse. The interesting part is that the survival data isn't even final yet. The company said follow-up is ongoing, and at the time they crunched the numbers, one-third of the patients were still alive. They expect the survival outcomes to "further mature" and plan to share more details at upcoming scientific meetings. Think of it as a preview of a movie that's still being edited—the early cut looks good, and the final version could be even better.

Can-Fite finished enrolling patients for this pancreatic cancer trial back in January. The full set of topline efficacy data—the big, official results—isn't expected until the third quarter of 2026. That's a long time to wait, but in the world of drug development, it's a standard timeline.

Now, here's where it gets more interesting. The company isn't putting all its eggs in the pancreatic cancer basket. It's also looking at whether Namodenoson can help with advanced liver cancer. And in a plot twist that sounds like it's from a different movie, Can-Fite got a Canadian patent in February covering the use of Namodenoson for reducing fat mass and body weight. Yes, you read that right. The same molecule being tested for cancer might also become an anti-obesity therapy. The patent gives them intellectual property protection for that use, which is valuable if they decide to go down that road.

In another bit of news from February, the company reported that a patient with advanced, decompensated liver cirrhosis who was treated with Namodenoson later had a successful liver transplant. It's a single case, so you can't draw broad conclusions, but it's a positive anecdote that adds to the story.

So, what did the market think of all this? The stock reaction was dramatic. Can-Fite shares were up 108% at $10.40. For context, the stock had been trading near its 52-week low of $3.63. When you're a micro-cap biotech, positive clinical data can send your stock on a rocket ride, and that's exactly what happened here. It's a reminder of the high-risk, high-reward nature of investing in companies that are still trying to prove their science works.